Compare Revvity Inc (RVTY) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 3.1× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| RVTY | VCSH | |
|---|---|---|
Market Cap | $16.98B | $51.90B |
Volume | 1,456,900 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $157.36 | $80.20 |
52-Week Low | $82.26 | $77.03 |
Typical Hold Time | 12 Days | 52 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
VCSH trades at $77.30 with minimal daily movement (+0.04%). The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights VCSH's competitive 4.5-4.8% dividend yield and low 0.03% expense ratio, though credit spreads remain tight. The ETF's short 2.7-year duration provides some protection against rising rates.
VCSH offers stable income exposure to investment-grade corporate bonds but faces headwinds from tight credit spreads and limited price appreciation potential. The fund's low duration minimizes interest rate risk, making it suitable for conservative investors seeking yield above Treasury alternatives, though corporate credit risk remains a consideration in economic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
